WO2014207664A3 - Composition pharmaceutique stable d'asénapine - Google Patents

Composition pharmaceutique stable d'asénapine Download PDF

Info

Publication number
WO2014207664A3
WO2014207664A3 PCT/IB2014/062575 IB2014062575W WO2014207664A3 WO 2014207664 A3 WO2014207664 A3 WO 2014207664A3 IB 2014062575 W IB2014062575 W IB 2014062575W WO 2014207664 A3 WO2014207664 A3 WO 2014207664A3
Authority
WO
WIPO (PCT)
Prior art keywords
asenapine
pharmaceutical composition
stable pharmaceutical
pharmaceutically acceptable
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2014/062575
Other languages
English (en)
Other versions
WO2014207664A2 (fr
Inventor
Veerababu Ramabrahmmam Taduri
Viral Ramesh VAIDYA
Jigar Rameshchandra LALANI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alembic Pharmaceuticals Ltd
Original Assignee
Alembic Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alembic Pharmaceuticals Ltd filed Critical Alembic Pharmaceuticals Ltd
Publication of WO2014207664A2 publication Critical patent/WO2014207664A2/fr
Publication of WO2014207664A3 publication Critical patent/WO2014207664A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition pharmaceutique stable pour l'administration par voie buccale et/ou sublinguale comprenant de l'asénapine ou un de ses sel pharmaceutiquement acceptable, un antioxydant, un polymère soluble dans l'eau, un diluant soluble dans l'eau, un délitant et éventuellement un ou plusieurs excipients pharmaceutiquement acceptables présentant une biodisponibilité améliorée ou bioéquivalente au produit commercialisé Saphris ®, Sycrest ® et un procédé de préparation de ceux-ci.
PCT/IB2014/062575 2013-06-28 2014-06-25 Composition pharmaceutique stable d'asénapine Ceased WO2014207664A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2206/MUM/2013 2013-06-28
IN2206MU2013 IN2013MU02206A (fr) 2013-06-28 2014-06-25

Publications (2)

Publication Number Publication Date
WO2014207664A2 WO2014207664A2 (fr) 2014-12-31
WO2014207664A3 true WO2014207664A3 (fr) 2015-04-02

Family

ID=52142775

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2014/062575 Ceased WO2014207664A2 (fr) 2013-06-28 2014-06-25 Composition pharmaceutique stable d'asénapine

Country Status (2)

Country Link
IN (1) IN2013MU02206A (fr)
WO (1) WO2014207664A2 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10898449B2 (en) 2016-12-20 2021-01-26 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
US11033512B2 (en) 2017-06-26 2021-06-15 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer
US11337932B2 (en) 2016-12-20 2022-05-24 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
US11648213B2 (en) 2018-06-20 2023-05-16 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
US12329862B2 (en) 2018-06-20 2025-06-17 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015125152A2 (fr) * 2014-02-18 2015-08-27 Hetero Research Foundation Compositions pharmaceutiques d'asénapine
US10085971B2 (en) 2016-08-22 2018-10-02 Navinta Iii Inc Pharmaceutical solution of asenapine for sublingual or buccal use
CN109288800A (zh) * 2018-10-30 2019-02-01 天津仁生医药科技有限公司 马来酸阿塞那平片及其制备方法
CN109330984A (zh) * 2018-11-20 2019-02-15 天津仁生医药科技有限公司 一种马来酸阿塞那平舌下片及其制备方法
KR102883506B1 (ko) * 2019-10-28 2025-11-12 히사미쓰 세이야꾸 가부시키가이샤 아세나핀-n-옥사이드의 생성을 억제하는 방법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763476A (en) * 1994-03-02 1998-06-09 Akzo Noble N.V. Sublingual or buccal pharmaceutical composition
WO2012123325A1 (fr) * 2011-03-11 2012-09-20 Medichem S.A. Nouvelles formes cristallines du sel de trans-5-chloro-2-méthyl-2,3,3a,12b-tétrahydro-1h-dibenzo[2,3:6,7] oxépino[4,5-c]pyrrole avec l'acide maléique

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763476A (en) * 1994-03-02 1998-06-09 Akzo Noble N.V. Sublingual or buccal pharmaceutical composition
WO2012123325A1 (fr) * 2011-03-11 2012-09-20 Medichem S.A. Nouvelles formes cristallines du sel de trans-5-chloro-2-méthyl-2,3,3a,12b-tétrahydro-1h-dibenzo[2,3:6,7] oxépino[4,5-c]pyrrole avec l'acide maléique

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10898449B2 (en) 2016-12-20 2021-01-26 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
US10980753B2 (en) 2016-12-20 2021-04-20 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
US11337932B2 (en) 2016-12-20 2022-05-24 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
US12138353B2 (en) 2016-12-20 2024-11-12 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
US12485099B2 (en) 2016-12-20 2025-12-02 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
US11033512B2 (en) 2017-06-26 2021-06-15 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer
US11648213B2 (en) 2018-06-20 2023-05-16 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
US12329862B2 (en) 2018-06-20 2025-06-17 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine

Also Published As

Publication number Publication date
WO2014207664A2 (fr) 2014-12-31
IN2013MU02206A (fr) 2015-06-12

Similar Documents

Publication Publication Date Title
WO2014207664A3 (fr) Composition pharmaceutique stable d'asénapine
WO2013188273A8 (fr) Composition pharmaceutique ophtalmique topique contenant de l'axitinib
WO2010092090A3 (fr) Nouveaux sels de la sitagliptine
WO2014016754A3 (fr) Compositions pharmaceutiques d'inhibiteur de la pompe à protons
WO2009066315A3 (fr) Compositions à libération prolongée de trimétazidine et procédé de préparation
WO2013188268A8 (fr) Composition pharmaceutique ophtalmique topique contenant du pazopanib
WO2012135615A3 (fr) Enopeptines, utilisations de celles-ci, et procédés de synthèse de celles-ci
CA2863376A1 (fr) Comprimes gastro-resistants
WO2011141488A3 (fr) Compositions pharmaceutiques comprenant de l'hydromorphone et de la naloxone
HK1208222A1 (en) Modified release formulations for oprozomib
WO2014033526A9 (fr) Compositions pharmaceutiques d'étoricoxib
WO2010070677A3 (fr) Procédé de préparation de prasugrel et de ses sels pharmaceutiquement acceptables
WO2015125152A3 (fr) Compositions pharmaceutiques d'asénapine
WO2010046932A3 (fr) Composition pharmaceutique de minocycline à libération prolongée et son procédé
EP3216450A8 (fr) Préparation pharmaceutique comprenant un inhibiteur de la cycline et son procédé de préparation
WO2012108631A3 (fr) Compositions pharmaceutiques comprenant des nanoparticules qui contiennent du révaprazan et procédés de préparation associés
WO2015002755A3 (fr) Composés pour le traitement du paludisme
WO2017098533A3 (fr) Procédé de préparation de lisdexamphétamine
WO2014125504A3 (fr) Compositions pharmaceutiques de fébuxostat
WO2010137040A3 (fr) Nouvelles compositions pharmaceutiques de ranolazine
WO2013188279A8 (fr) Composition pharmaceutique ophtalmique topique contenant du cediranib
WO2017034242A3 (fr) Nouveau dérivé de catéchol et composition pharmaceutique le comprenant
WO2016197042A8 (fr) Formulations à libération modifiée ou ciblée de linaclotide
HK1206269A1 (en) Pharmaceutical formulation comprising bendamustine
MX370184B (es) Composición farmacéutica que comprende fingolimod.

Legal Events

Date Code Title Description
122 Ep: pct application non-entry in european phase

Ref document number: 14817924

Country of ref document: EP

Kind code of ref document: A2